Compare Boston Scientific Corporation (BSX) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs iShares Silver Trust — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while iShares Silver Trust trades at $59.75. The key difference: iShares Silver Trust is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | SLV | |
|---|---|---|
Market Cap | $71.46B | — |
Sector | Health | — |
52-Week High | $108.14 | $105.57 |
52-Week Low | $42.63 | $33.89 |
Enterprise Value | $83.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
SLV (iShares Silver Trust) trades at $57.50, up 2.95% with a bullish technical signal supported by moving averages. The ETF provides direct exposure to physical silver, which has seen volatile trading after a 50% decline from early 2026 highs. Recent price action shows silver rebounding amid Fed policy uncertainty and strong industrial demand fundamentals.
Silver's outlook remains compelling due to constrained supply and growing industrial demand, though high volatility and Fed policy sensitivity pose risks. The current technical setup suggests potential for continued upside if silver maintains support above $56, with resistance near $59.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
